EU ADR Reporting Guidance Remains Complex, But Addresses Some Of Industry’s Concerns
Executive Summary
Europe’s drug industry trade group EFPIA says that the recently-finalized EU guideline on reporting adverse drug reactions remains complex and detailed, but it is pleased that some of the new requirements have been simplified or brought into line with international practice.
You may also be interested in...
EMA Pilot To Help Companies ‘Ease In’ To New EudraVigilance System
The European Medicines Agency will use a phased approach to help companies comply with their obligation to monitor the revamped EU pharmacovigilance database and to report validated signals. Under a pilot to be launched on Feb. 22, 2018, companies will only have to monitor and report signals on drugs under additional monitoring.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.